Sera Prognostics, Inc. (SERA)
Nasdaq · Healthcare · Medical Devices
$2.00−4.31%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $78.9M
- 52-week range
- $1.56 – $3.95
- 52-week change
- −35.89%
- EPS (trailing)
- −$0.67
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $81K (+5.19%)
- Net income
- −$31.9M
- Operating margin
- −45066.7%
- Diluted EPS
- −$0.67
- Free cash flow
- −$26.4M
From the company’s annual report on SEC EDGAR.
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Headquarters: Salt Lake City, United States · 71 employees · sera.com